CTI BioPharma (FRA:CEPS) ROCE % : -74.99% (As of Mar. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CTI BioPharma's annualized ROCE % for the quarter that ended in Mar. 2023 was -74.99%.

CTI BioPharma ROCE % Historical Data

The historical data trend for CTI BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma ROCE % Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-54.67

-82.79

-143.56

-435.78

-314.09

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial															-736.17	-109.93	-48.82	-73.76	-74.99

CTI BioPharma ROCE % Calculation

CTI BioPharma's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-74.441	/	( ( (64.104 - 58.986)	+	(118.873 - 76.59) )	/ 2 )
	=	-74.441	/	( (5.118	+	42.283)	/ 2 )
	=	-74.441	/	23.7005
	=	-314.09 %

CTI BioPharma's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	-31.28	/	( ( (118.873 - 76.59)	+	(104.862 - 63.723) )	/ 2 )
	=	-31.28	/	( ( 42.283	+	41.139 )	/ 2 )
	=	-31.28	/	41.711
	=	-74.99 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

CTI BioPharma (FRA:CEPS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CTI BioPharma ROCE % Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (FRA:CEPS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines